002630 (002630) Fair Value & Analysis
Healthcare · Market cap 58.3B KRW
Fair value as of: Jun 25, 2026
From 2 valuation models · updated 7 days ago
Share price −8.4% over the past month.
Price vs Fair Value (12 months)
12‑month range 432.79 KRW – 2,308 KRW · fair‑value band 4,090 KRW – 6,816 KRW · the 793.00 KRW price screens below the 5,453 KRW fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
002630 (002630) currently trades at 793.00 KRW, while our model-based Fair Value estimate is 5,453 KRW — implying the stock looks roughly 587.6% undervalued today. We read business quality at 39/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, 002630 generated revenue of 59.1B KRW at a net margin of -11.6%. Revenue grew 21.8% year over year. It earns a return on equity of -12.4%. The balance sheet holds a net cash position of 22.6B KRW. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
002630 reported revenue of 29.4B KRW in FY2025 versus 52.0B KRW in FY2021, a compound −13.3%/yr. Reported net income was −13.2B KRW in FY2025.
Is 002630 fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 002630 (002630) undervalued?
What is the fair value of 002630?
What is the quality score of 002630?
What is the revenue of 002630 (002630)?
What is the net profit margin of 002630?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.